Lytic Peptides: The Ultimate Cancer Weapon: Stanley Lewis, A28 Therapeutics

What if we could destroy cancer cells using a completely novel payload—one that doesn't rely on traditional chemotherapy or even antibody-drug conjugates, but instead uses lytic peptides to obliterate tumors?In this episode, Dr. Stanley Lewis, CEO of A28 Therapeutics, shares how his company is pioneering lytic peptides as a next-generation cancer therapy, offering a fundamentally different approach to killing cancer cells.What we discuss:• The vision behind A28 Therapeutics and the science of lytic peptides• How lytic peptides work differently from traditional cancer payloads• Why this approach could overcome resistance mechanisms that limit other therapies• The role of AI and machine learning in drug discovery and peptide design• Fundraising strategies and building investor confidence in novel modalities• Leadership and culture: assembling a team to tackle cancer differently• Personal reflections on the future of oncology and transformative therapeuticsThis isn't another antibody-drug conjugate. This is a completely different way to kill cancer.About the Guest: Dr. Stanley Lewis is CEO of A28 Therapeutics, a biotechnology company developing novel lytic peptide-based cancer therapeutics.About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.🔗 Connect:• A28 Therapeutics: [https://a28therapeutics.com]• Stanley Lewis: [https://www.linkedin.com/in/stanley-t-lewis-md-mph]• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]📧 Questions or guest suggestions? [[email protected]]#Biotech #Cancer #Oncology #LyticPeptides #DrugDiscovery #ArtificialIntelligence #NovelTherapeutics #Innovation